(0.15%) 5 139.00 points
(0.10%) 38 478 points
(0.23%) 17 888 points
(-0.25%) $83.64
(1.72%) $1.956
(0.13%) $2 350.30
(0.62%) $27.71
(1.54%) $936.30
(-0.16%) $0.933
(-0.32%) $10.99
(-0.32%) $0.798
(1.15%) $92.93
Live Chart Being Loaded With Signals
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria...
Stats | |
---|---|
本日の出来高 | 168 084 |
平均出来高 | 2.65M |
時価総額 | 19.33M |
EPS | $0 ( 2024-04-03 ) |
次の収益日 | ( $-0.0700 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.690 |
ATR14 | $0.00500 (1.43%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Blum Susan | Buy | 0 | |
2024-03-16 | Cystic Fibrosis Foundation | Sell | 0 | Common Stock, par value $0.0001 per share |
2024-03-16 | Cystic Fibrosis Foundation | Sell | 21 635 000 | Series X Preferred Stock |
2024-03-16 | Cystic Fibrosis Foundation | Sell | 10 817 500 | Warrant to purchase common stock |
2024-03-16 | Cystic Fibrosis Foundation | Sell | 4 778 265 | Warrant to purchase common stock |
INSIDER POWER |
---|
-67.65 |
Last 91 transactions |
Buy: 9 333 285 | Sell: 39 545 482 |
ボリューム 相関
Biomx Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Biomx Inc 相関 - 通貨/商品
Biomx Inc 財務諸表
Annual | 2023 |
収益: | $-357 000 |
総利益: | $-1.23M (343.98 %) |
EPS: | $-0.510 |
FY | 2023 |
収益: | $-357 000 |
総利益: | $-1.23M (343.98 %) |
EPS: | $-0.510 |
FY | 2022 |
収益: | $-134 000 |
総利益: | $-2.65M (1 980.60 %) |
EPS: | $-0.950 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $1.393 |
Financial Reports:
No articles found.
Biomx Inc
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。